Does semaglutide raise kidney risk more than tirzepatide?

If you are choosing between semaglutide and tirzepatide, or already taking one, a new safety analysis gives you a reason to pay attention to your kidneys. Researchers compared adverse event reports for the two most-used GLP-1 medications and found semaglutide flagged for acute kidney injury at more than twice the rate of tirzepatide. The headline number sounds alarming. The real story is more useful, and most of it is in your control.

TL;DR

A FAERS pharmacovigilance study of 133,872 reports found semaglutide (Ozempic, Wegovy) had an acute kidney injury reporting rate of 1.07%, versus 0.47% for tirzepatide (Mounjaro, Zepbound). Only semaglutide crossed the statistical signal threshold. The absolute risk stays low, and most of these cases trace back to dehydration, which you can prevent by managing GI side effects and keeping your fluids and electrolytes up.

What the study actually found

The analysis, published in the Journal of Clinical Medicine in October 2025, pulled every relevant report from the FDA Adverse Event Reporting System (FAERS) between January 2022 and September 2025. That came to 133,872 reports in total: 92,807 for tirzepatide and 41,065 for semaglutide.

Then the researchers counted acute kidney injury cases, using a broad definition that included renal failure, renal impairment, tubulointerstitial nephritis and a few related terms. Here is what the two drugs looked like side by side:

• Semaglutide: 440 acute kidney injury cases out of 41,065 reports, a rate of 1.07%
• Tirzepatide: 432 cases out of 92,807 reports, a rate of 0.47%
• Semaglutide's proportional rate was more than double tirzepatide's

When they ran the standard pharmacovigilance math, the reporting odds ratio for tirzepatide versus semaglutide was 0.44 (95% confidence interval 0.38 to 0.50). In plain terms, kidney injury showed up disproportionately often in semaglutide reports and not in tirzepatide reports. Semaglutide crossed the conventional threshold that flags a safety signal worth investigating. Tirzepatide did not.

The serious outcomes followed the same pattern. Among the semaglutide kidney cases there were 28 deaths, 11 disabilities, 243 hospitalizations and 36 life-threatening events. Among the tirzepatide cases: 16 deaths, 6 disabilities, 209 hospitalizations and 11 life-threatening events. These are raw report counts, not rates, but the direction is consistent.

Why report counts are not the same as your risk

Before you switch drugs over this, read this section carefully, because it changes how much weight the headline deserves.

FAERS is a spontaneous reporting database. Anyone - a doctor, a pharmacist, a patient, a lawyer - can file a report, and nobody verifies that the drug caused the event. More importantly, FAERS has no denominator. It knows how many reports came in, but not how many people actually took the drug. So a "1.07% reporting rate" is 1.07% of reports, not 1.07% of users. The authors flag this themselves as the study's biggest limitation.

Several things can inflate a signal without any real difference in danger. Semaglutide has been on the market longer and is prescribed to an older, sicker diabetes population in many cases, which naturally carries more kidney risk to begin with. Media attention and lawsuits drive reporting too - a drug in the headlines gets more reports filed for the same event. A disproportionality signal is a flag that says "look here", not a verdict that says "this drug damages kidneys more."

What the study is good for: it tells you kidney injury is a real, if uncommon, thing to watch for on GLP-1 medications, and it is worth a little more caution with semaglutide. What it cannot tell you: your personal odds, or whether the drug or the dehydration around it did the damage. As the authors put it, the overall frequency of GLP-1-associated kidney injury in practice appears low.

Why GLP-1 medications can stress the kidneys at all

The mechanism is not mysterious, and it points straight at the fix. Almost all of these kidney injuries are what doctors call pre-renal, meaning the kidney itself is usually healthy - it is just not getting enough blood flow because the body is short on fluid.

Where does the fluid go? Straight out through the most common GLP-1 side effects. Nausea cuts how much you drink. Vomiting and diarrhea pour water and electrolytes out faster than you replace them. Add the appetite suppression that is the whole point of the drug, and a lot of people are quietly running a litre or two low on fluid for days at a time, especially in the first weeks or after a dose increase. The kidney takes the hit.

Tirzepatide and semaglutide both cause GI side effects, but their profiles differ, and semaglutide's nausea and vomiting pattern may push more people toward the dehydration that triggers pre-renal injury. That is one plausible reason the signal landed on semaglutide and not tirzepatide, though the study was not designed to prove it.

Two more things raise the stakes. First, common medicines stack the risk: NSAID painkillers like ibuprofen, plus blood pressure drugs like ACE inhibitors, ARBs and diuretics, all reduce the kidney's ability to cope with low fluid. Get dehydrated while taking those, and a manageable situation becomes a dangerous one. Second, this acute risk is a completely separate question from the long-term kidney picture. In people with chronic kidney disease, semaglutide is actually protective over years, which we covered in our breakdown of what the FLOW trial shows about semaglutide and kidney disease. Short-term dehydration risk and long-term kidney protection can both be true at once.

How to protect your kidneys on a GLP-1

This is the part that matters, because nearly every step is preventable. None of it requires switching drugs. Treat this as a conversation to have with your prescriber, not a set of rules to self-apply.

1. Drink on a schedule, not on thirst. By the time you feel thirsty on a GLP-1, you are already behind, because the drug blunts the appetite and thirst cues you would normally rely on. Aim for steady water through the day rather than catching up at night.
2. Replace electrolytes, not just water. Vomiting and diarrhea drain sodium, potassium and magnesium along with the fluid. Plain water alone can leave you low on the minerals your kidneys and muscles need. Magnesium in particular runs low in a lot of GLP-1 users even before any illness.
3. Have a sick-day plan. If you get hit with a vomiting or diarrhea bug and cannot keep fluids down, that is exactly when kidney injury happens. Ask your clinician in advance whether you should pause the GLP-1, and any NSAIDs or blood pressure pills, until you can drink normally again. This "sick-day rule" is standard advice for other kidney-stressing drugs.
4. Go easy on ibuprofen and naproxen. NSAIDs plus dehydration is the classic recipe for pre-renal injury. Reach for other options when you can, especially during a rough patch of GI side effects.
5. Manage nausea early. Controlling the nausea is not just about comfort, it is what keeps you drinking. Smaller meals, slower titration and anti-nausea strategies all protect your fluid balance indirectly.
6. Know the warning signs. Much less urine than usual, dark urine, swelling in the legs or face, unusual fatigue or confusion - any of these during a bout of vomiting or diarrhea is a reason to call your clinician, not wait it out.

The electrolyte and mineral side of this is where nutrition does real work. When food intake drops by a quarter or more and GI side effects periodically flush out what you do eat, minerals like magnesium and potassium are among the first to run short, and they are the same ones your kidneys and muscles depend on. This is the exact gap GLP-1 Shield is built to close: the specific nutrients that quietly drain away when a medication cuts your intake, so a stomach bug does not turn into something your kidneys have to pay for.

So is tirzepatide the safer choice?

Not so fast. This one study, on its own, is a reporting signal, not proof that tirzepatide is kidney-safer in real life. Choosing between the two drugs comes down to a lot more than a single FAERS analysis - efficacy, cost, GI tolerance, insurance coverage and your own medical history all weigh in. If you want the fuller comparison, we laid it out in what the 2026 clinical trials actually show about semaglutide versus tirzepatide. The honest takeaway here is narrower: whichever GLP-1 you are on, dehydration is the kidney risk you can see coming, and the one you can head off.

Frequently asked questions

Does Ozempic cause kidney damage?

Serious kidney injury on semaglutide (Ozempic, Wegovy) is uncommon, but it does happen, usually through dehydration when nausea, vomiting or diarrhea leave you short on fluid. A 2025 FAERS analysis found semaglutide flagged for acute kidney injury more often than tirzepatide. The absolute risk is low, and staying hydrated is the single best protection.

Is tirzepatide safer for the kidneys than semaglutide?

One pharmacovigilance study found tirzepatide had a lower acute kidney injury reporting rate (0.47% versus 1.07%), but reporting rates are not the same as real-world risk. It is not enough on its own to call tirzepatide kidney-safer. The kidney risk on either drug is mostly about dehydration, which you can manage regardless of which one you take.

What are the signs of kidney problems on a GLP-1?

Watch for a big drop in how much you urinate, dark urine, swelling in the legs, ankles or face, unusual tiredness, or confusion, especially during a spell of vomiting or diarrhea. Any of these is a reason to contact your clinician promptly rather than pushing through.

Should I stop my GLP-1 if I get sick with vomiting or diarrhea?

Possibly, and it is worth asking your prescriber before it happens. When you cannot keep fluids down, continuing a GLP-1 along with NSAIDs or certain blood pressure medications raises the risk of kidney injury. Many clinicians advise a temporary pause on those medicines until you can drink and eat normally again.